BioSpace News Archive

– In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study. – AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism.

Growing demand for younger skin and minimal invasion procedures has fuelled the need for integrated fat transfer procedures.

Botulism (or botulism poisoning) is an uncommon, yet intense disease that transmits through food, contact with tainted soil, or through an open injury. Without early treatment, botulism can lead to paralysis, breathing challenges, and death.

Emergency medical supplies are an integral part of a health care system. These comprise specialized equipment and products to aid in the provision of emergency care.

Hedgehog proteins consist of a group of proteins that regulate cell differentiation, growth, and survival. These proteins are involved in organogenesis and have shown to promote adult stem cell proliferation.

Several biological substances or products are used in the treatment of ulcers, including skin grafts and substitutes, biologic wound dressings, and growth factors.

Core One Labs Inc., is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. has commenced the development of its next-generation patent pending psychedelic drug formulation for the treatment of Alzheimer’s Disease.

Brain Navi Biotechnology Co., Ltd., a brain surgery robotic company, is launching “zero-contact” medical stations in hospitals across Taiwan, fully protect medical staff and patients from the cross-infection of “highly contagious diseases.” The biggest risk of infection for medical staff is during intubation, nasal swabbing, and personal protective equipment removal, says Dr. Jerry Chen, the Brain Navi CEO.

Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology and the Catalan Institute of Research and Advanced Studies in Barcelona, reported that on Tuesday 4th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d’Hebron in Barcelona.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the following upcoming investor relations event.